SNV1521 in Participants With Advanced Solid Tumors

Recruiting now · Phase 1

Conditions studied: Advanced Solid Tumor

In brief

This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one. They are also investigating whether it can be combined with other cancer therapies.

Key facts

Study ID

NCT06220864

Run by

Synnovation Therapeutics, Inc.

People needed

400

Starts

2024-02-23

Expected to finish

2027-12-01

Last updated by the study team

2026-06-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Advanced or metastatic solid tumor malignancy
• Evaluable or Measurable disease (RECIST 1.1 Criteria).
• ECOG Performance Status 0 or 1.
• Life expectancy > 3 months

You may not qualify if…

• History of other malignancy within the past 2 years
• Prior diagnosis of Myelodysplastic syndrome or Acute Myeloid Leukemia
• Significant cardiovascular disease within 6 months
• Significant gastrointestinal disease
• HIV infection with a CD4+ T-cell count < 200 cells/μL and/or a detectable viral load
• Liver dysfunction

Where it is running

• Smilow Cancer Hospital at Yale New Haven — New Haven, Connecticut, United States (enrolling)
• Thomas Jefferson University — Philadelphia, Pennsylvania, United States (enrolling)
• Sarah Cannon Research Institute — Nashville, Tennessee, United States (enrolling)
• The University of Texas M.D. Anderson Cancer Center — Houston, Texas, United States (enrolling)
• START Center for Cancer Care — West Valley City, Utah, United States (enrolling)
• Scientia Clinical Research — Randwick, New South Wales, Australia (enrolling)
• Princess Alexandra Hospital — Woolloongabba, Queensland, Australia (enrolling)
• Monash Health — Clayton, Victoria, Australia (enrolling)
• The Alfred Hospital — Melbourne, Victoria, Australia (enrolling)
• Linear Clinical Research — Crawley, Western Australia, Australia (enrolling)
• The Institut Jules Bordet — Brussels, Belgium (enrolling)
• University Center for Clinical Research Antwerp (UNICCRA) — Edegem, Belgium (enrolling)
• AZ Maria Middelares — Ghent, Belgium (enrolling)
• AZ Groeninge — Kortrijk, Belgium (enrolling)
• Arthur J.E. Child Comprehensive Cancer Centre — Calgary, Alberta, Canada (enrolling)
• Princess Margaret Hospital — Toronto, Ontario, Canada (enrolling)
• Institut Bergonie — Bordeaux, France (enrolling)
• UNICANCER - Centre Leon-Berard (CLB) — Lyon, France (enrolling)
• Gustave Roussy — Villejuif, France (enrolling)
• Istituto Clinico Humanitas — Milan, Italy (enrolling)
• Istituto Europeo di Oncologia (IEO) (European Institute of Oncology) — Milan, Italy (enrolling)
• NEXT Oncology - Barcelona — Barcelona, Spain (enrolling)
• Vall d'Hebron University Hospital — Barcelona, Spain (enrolling)
• The START Center for Cancer Care - Madrid - CIOCC - Hospital Universitario Madrid Sanchinarro — Madrid, Spain (enrolling)
• NEXT Oncology - Hospital Quironsalud Madrid — Madrid, Spain (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.